What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Belimumab shows moderate clinical effectiveness, with evidence from the BLISS trials indicating a statistically significant improvement in the SRI-4 response rate at 52 weeks compared to standard therapy. However, the long-term benefits remain uncertain due to the short duration of trials and lack of direct comparison with rituximab.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for belimumab are within acceptable ranges, with an ICER of £12,335 per QALY for the intravenous formulation. The committee acknowledged uncertainties but considered the unmet need for effective treatments in systemic lupus erythematosus.
Is there quality-of-life evidence payers weigh? — Quality of life
Patient testimonies indicate that treatment with belimumab has led to significant improvements in daily functioning and overall quality of life, particularly in reducing disease flares and corticosteroid use. However, some negative aspects related to treatment burden were noted.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Belimumab has an acceptable safety profile, with mostly mild to moderate adverse events reported. Patient experts noted manageable side effects, and the treatment is considered safer than alternatives like rituximab.
Was the drug compared against what payers expect? — Comparator Selection
The committee recognized standard therapy and rituximab as relevant comparators. The evidence supports the use of belimumab as an add-on therapy to standard care, although the lack of direct comparison with rituximab introduces some uncertainty.
Is the population defined the way payers need it? — Patient Population and Subgroups
The updated patient population for belimumab is considered appropriate, allowing broader access for patients with high disease activity. However, there are still concerns regarding the representativeness of the trial population.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Belimumab can be integrated into existing care pathways with minor adjustments, particularly with the availability of a subcutaneous formulation that allows for self-administration, improving patient access.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of belimumab are manageable, with the potential for cost savings through reduced corticosteroid use and hospital visits. However, the overall budget impact remains a consideration.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes multiple trials and real-world data, although there are some methodological concerns and uncertainties regarding long-term effectiveness and direct comparisons.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness of belimumab, particularly in comparison to rituximab. The committee noted that these uncertainties could impact the overall decision-making process.
